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Abstract
Patients with diabetes mellitus are at risk for two acute metabolic complications:
severe hyperglycemia and hypoglycemia. These acute complications are costly and
associated with significant morbidity and mortality, but are preventable with delivery of
high-quality care. The purpose of this work is to focus on a subset of these complications
which are iatrogenic, i.e., caused by medical treatment. Hospital-acquired diabetic
ketoacidosis (DKA) is an iatrogenic complication as it occurs when a patient with known
diabetes experiences DKA while hospitalized for other reasons. Hypoglycemia is an
adverse effect of treatment and thus, by definition, all hypoglycemia resulting from the
use of glucose-lowering medications in the outpatient setting is iatrogenic. Reducing the
occurrence of these iatrogenic complications of diabetes can improve patient health
outcomes and reduce costs. However, prevention requires targeted interventions based on
a detailed understanding of precipitating factors. In order to address these iatrogenic
complications, we performed two analyses to examine factors driving their occurrence.
The first analysis is a retrospective chart review of hospitalized adults with
diabetes who developed DKA during a hospital admission at a single local hospital.
Twenty-seven patients were included in this analysis over 5 years. The patients were
predominantly White (70.4%) and middle-aged (average age 53.4 years). Most had a
documented diagnosis of type 1 diabetes (59.3%) and all but 1 patient were on insulin at
home. At the time of DKA, 51.9% were on medicine or neurology services, 33.3% on
surgery or ob/gyn, and 14.8% on podiatry. Using common cause analysis, the most
prevalent reason for DKA was a problem with insulin dosing, including missed doses of
insulin (n=7, 25.9%) and insulin dose reductions of 50% or greater (n=8, 29.6%). The
remaining cases were caused by steroids (n=4, 13.8%), infection (n=4, 13.8%), and acute
stress associated with surgery or shock (n=4, 13.8%).
The second analysis is a retrospective analysis of factors that mediate severe
hypoglycemia requiring an ED visit or hospitalization in an insured population in
California. A total of 305,310 adults with diabetes were included in this analysis. Among
the full cohort, the rate of severe hypoglycemia requiring an ED visit or hospitalization
was 7.4 per 1,000 person-years, but this varied significantly by race. Among Black vs
White patients, the rates were 13.64 vs 9.27 per 1,000 person-years, respectively. Given
the significance of these racial disparities, factors mediating these disparities were further
explored. Differences in insulin use by race were not significant, and racial disparities
persisted among patients on insulin. Rates of hypoglycemia among Black vs White
patients on insulin were 34.72 [95% CI 30.09, 38.87] vs 27.14 [25.38, 28.98] per 1000
person-years, respectively. Factors mediating the racial differences in ED visits and
hospitalizations for severe hypoglycemia were investigated using literature review and
clinical expert input and a directed acyclic graph (DAG) was created to depict the causal
relationships of the proposed mediator variables. Analytic work for this project is
ongoing. To analyze our DAG, we plan to assess the causal impact of each proposed
mediator variable by using inverse probability weighting to estimate counterfactual
disparity measures.
Together, these projects demonstrate the importance of thorough analysis of
factors that mediate and precipitate iatrogenic complications. In the case of hospitalacquired DKA, interventions targeting inappropriate insulin dosing among hospitalized

patients with diabetes could potentially prevent over 50% of cases. For severe outpatient
hypoglycemia, quantifying the causal impact of each proposed mediator variable in the
DAG will reveal high-yield opportunities to address disparities in hypoglycemia.
Ongoing work on both projects continues to improve understanding of these problems
and will ultimately facilitate implementation of targeted prevention strategies.
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Introduction
Diabetes and its Complications
More than 10% of US adults have diabetes mellitus.1 People with diabetes are more
than three times as likely to be hospitalized as people without diabetes, and they make up
25-30% of all hospitalized adults in the US.1-5 In 2014 alone, this resulted in 7.4 million
discharges from US hospitals with diabetes listed as a diagnosis.6 In addition to more
frequent admissions and readmissions, patients with diabetes stay in the hospital
longer.7,8 As a result, costs associated with diabetes in the US are substantial. In 2017,
diabetes cost the US $327 billion, including $237 billion in direct medical expenses.9 The
burden of diabetes on the health and economy of the US continues to increase year after
year as the US population with diabetes increases.9 A large proportion of the morbidity,
mortality, and cost associated with diabetes is attributable to diabetic complications,
which can be long-term or acute.9,10
Most long-term complications of diabetes result from chronic elevations in blood
glucose levels due to a relative or absolute insulin deficiency. Chronic hyperglycemia can
cause accumulation of advanced-glycation end products and reactive oxygen species as
well as activation of inflammatory pathways.11,12 These processes cause tissue damage
and result in peripheral neuropathy, retinopathy, nephropathy, micro and macrovascular
disease. Over 55% of US patients with diabetes are affected by at least one of these
chronic diabetic complications and 7.6% are affected by four or more.13 The knowledge
that chronic hyperglycemia is the cause of these complications has led to the
development of over 60 different glucose-lowering medications and widespread
implementation of evidence-based guidelines that recommend glycemic control,
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preventive screenings for microvascular complications, and cardiovascular risk reduction
strategies for all diabetic patients.14 Together, these strategies target long-term
complication risk and the associated morbidity and mortality.
Despite guidelines on diabetes care, maintaining glycemic control in diabetic patients
is challenging and medical intervention is not without risk. 15,16 Medical providers,
treatments, and procedures can all cause complications. These complications are known
as iatrogenic. Unlike the long-term complications discussed above, iatrogenic
complications of diabetes tend to be acute. Two important examples of iatrogenic
diabetic complications are hospital-acquired diabetic ketoacidosis and severe outpatient
hypoglycemia. These complications deserve special attention because they are potentially
avoidable and are an example of unintended consequences of medical care.

Hospital-Acquired Diabetic Ketoacidosis
Patients with diabetes are at risk for poor glycemic control both in and outside of the
hospital. Poor control of blood glucose levels in hospitalized patients with diabetes is
associated with increased morbidity and mortality.17-20 Despite this evidence and wellestablished guidelines on inpatient glucose management, hyperglycemia among
hospitalized patients remains prevalent.21-23 Studies have shown that close to one third of
all blood glucose measurements in the hospital are above the recommended threshold of
180mg/dL and one fifth of patients have sustained hyperglycemia. 21,22
The most acute and serious consequence of severe, sustained hyperglycemia is
diabetic ketoacidosis (DKA). DKA is defined by hyperglycemia, ketonemia, and
metabolic acidosis.24 It occurs due to a relative or absolute deficiency of insulin and a
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corresponding increase in counter-regulatory hormones, including glucagon. This
imbalance leads to impaired glucose utilization resulting in severe hyperglycemia. The
hyperglycemia itself can increase tonicity and cause glucose-induced osmotic diuresis,
leading to volume depletion and electrolyte disturbances. Inability to use glucose for fuel
also causes increased proteolysis, lipolysis, and ketogenesis resulting in ketoacidosis.
These processes together can cause life-threatening volume depletion, cerebral edema,
and electrolyte abnormalities and require prompt treatment with an insulin infusion and
fluid and electrolyte repletion.
Hospital-acquired DKA is DKA that occurs during a hospitalization and was not
present on admission. It can be life-threatening, but can be prevented through appropriate
management of patients with diabetes with insulin, a medication that is readily available
in the hospital. Therefore, it is considered a “never event” by the Centers for Medicare
and Medicaid Services.25 This means that hospitals do not receive additional payment for
cases of hospital-acquired DKA.
Few data on hospital-acquired DKA are available. One study in the UK found that
approximately 7.8% of all DKA cases are hospital-acquired.26 Another study of
hospitalized patients with diabetes in California found that hospital-acquired poor
glycemic control (including DKA, hyperglycemic hyperosmolar state, and severe
hypoglycemia) resulted in a significantly increased length of stay (14 vs 7 days),
increased cost of hospitalization ($26,125 vs $18,233), and mortality rate (16% vs 9%)
compared to matched controls.27
The consequences of hospital-acquired DKA are serious for patients, hospitals,
and healthcare systems. However, little is known about what factors precipitate the
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development of DKA in hospitalized patients. An understanding of the patient
population, clinical context, and precipitating factors of hospital-acquired DKA is an
essential first step in reducing its occurrence.
Severe Outpatient Hypoglycemia
Hypoglycemia is also a common, costly, and preventable problem among patients
with diabetes. It is an adverse effect of diabetes treatment and can either be mild (selftreated) or severe (requiring assistance of a third party to administer glucagon or
carbohydrates). Severe hypoglycemia event rates are estimated at 115 per 100 personyears among patients with type 1 diabetes and 35 per 100 person-years for patients with
type 2 diabetes.28-30
Severe hypoglycemia is detrimental to patient health and has been associated with an
increased risk of cognitive impairment, cardiovascular events, falls/fractures, and
death.31-36 It is also costly, with direct medical costs in the United States estimated at
$1.84 billion per year.37 Due to growing concerns about the significant adverse impact of
severe hypoglycemia on both patients and the healthcare system, considerable efforts are
now being made to prevent it.
The first step in prevention is identifying patients at risk. Not all patients with
diabetes are at elevated risk for severe hypoglycemia requiring an ED visit or
hospitalization. Approximately 5% of patients with diabetes account for >50% of severe
hypoglycemia events.38 Previous studies have identified many patient-level risk factors
for SH, including both clinical and demographic characteristics. 39-43 Many of these risk
factors make clinical sense such as use of certain glucose-lowering medications (e.g.,
insulin or sulfonylureas), older age, and chronic kidney disease.44 However, several
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studies have also demonstrated that Black patients with diabetes have a consistently
higher risk of severe hypoglycemia than White, Asian, or Latino patients.39-42
Rates of hospitalization for hypoglycemia are nearly four times higher among Black
patients compared to White patients and studies have shown that this difference has
remained unchanged for over 10 years.41 Similarly, the incidence of severe hypoglycemia
resulting in an ambulance call, ED visit, or hospitalization is close to two times higher
among Black patients compared to White patients.44 These racial differences persist
among patients with uniform access to care and among those treated with insulin or
sulfonylureas.39 Recent data demonstrate that the observed racial difference is increasing
due to increasing incidence of severe hypoglycemia among Black patients and relatively
stable incidence in other racial and ethnic groups.39
Although there is a history in the medical community of consideration of racial
differences in pathophysiology and treatment of disease, there is no scientific evidence
that racial disparities in severe hypoglycemia are caused by inherent biological
differences between races.45 This means that the observed racial disparities in severe
hypoglycemia are likely to be secondary to other unexplored differences in clinical,
social, or environmental factors. Prevention of severe hypoglycemia in diabetic patients
therefore requires further examination of the factors driving the observed racial
disparities.

Implications of this Research
Iatrogenic complications in general have a significant impact on morbidity, mortality,
and spending in all healthcare settings. Medical errors alone are estimated to account for
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over 400,000 deaths annually, making them the 3rd leading cause of death in the US.46
They cost the US approximately $19.5 billion per year including $17 billion in direct
medical expenses.47 Additional morbidity, mortality, and healthcare dollars associated
with other types of iatrogenic complications such as medication side effects and
negligence are more difficult to quantify, but are likely to be equally costly. Therefore,
iatrogenic complications are important opportunities to improve patient care and reduce
healthcare costs.
Among diabetic patients, hospital-acquired DKA and severe outpatient hypoglycemia
are examples of acute iatrogenic complications that are life-threatening and costly, but
preventable. Reducing the incidence of hospital-acquired DKA could not only reduce the
associated morbidity and mortality, but also shorten hospital stays and healthcare costs.
Similarly, reducing the incidence of severe outpatient hypoglycemia would reduce
morbidity and mortality as well as the number of unnecessary hospitalizations for
diabetic patients. Investigating and addressing factors that drive racial disparities in
hypoglycemia will focus prevention efforts on the most vulnerable patient populations
and ultimately work to close the observed racial gap.
Preventing iatrogenic complications requires understanding of the context in which
they occur. Assessing the relative causal contributions of patient factors, clinical settings,
and institutional environments is necessary in order to develop effective interventions.
There are different methodological approaches to the study of iatrogenic complications
and the choice of methods depends upon the goal of the project, the scientific question,
and the context of the study. This project uses two methods that are explained in detail in
the methods section below. Common cause analysis is applied to investigate hospital
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acquired DKA in the first study aim. Mediation analysis of directed acyclic graphs using
inverse probability weighting is applied to investigate racial disparities in severe
outpatient hypoglycemia in the second study aim. Both methodologies are effective,
efficient, and well-suited for the question and type of data in each project.
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Statement of Purpose and Hypotheses
The overall goal of this project is to examine the factors driving iatrogenic
complications of diabetes, including hospital-acquired DKA and severe outpatient
hypoglycemia. This overall goal has two specific aims:

Aim 1: Hospital-Acquired DKA
To characterize cases of hospital-acquired DKA in a large teaching hospital by
retrospective chart review using common cause analysis:
a. To describe clinical and demographic characteristics of patients who
develop DKA during a hospital admission
b. To identify common causes of hospital-acquired DKA
c. To propose solutions to common causes of hospital-acquired DKA
Hypothesis: We expect that the majority of hospital-acquired DKA will occur in patients
with type 1 diabetes because they are more likely to experience ketoacidosis than patients
with type 2 diabetes. Based on clinical experience and one previous study, we expect that
the majority of hospital-acquired DKA will occur due to inappropriate insulin dosing.48
We also anticipate that the majority of cases will occur on surgical or specialty services
since general medical providers have more experience managing diabetic patients and
will therefore be less likely to omit or inappropriately dose insulin. In addition, surgical
patients have frequent diet changes, including periods in which they are NPO for
procedures. These changes may necessitate frequent adjustments in insulin dose and
knowledge of appropriate glycemic control in patients with no oral intake, which may be
challenging when diabetes is not the primary reason for admission.
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Aim 2: Severe Outpatient Hypoglycemia
To identify factors mediating racial disparities in severe hypoglycemia requiring an ED
visit or hospitalization in a large insured population of adults with type 1 and type 2
diabetes:
a. To quantify racial and ethnic disparities in rates of severe outpatient
hypoglycemia overall and by insulin use
b. To use literature review and expert clinical knowledge to identify potential
factors that may mediate racial disparities
c. To use directed acyclic graphs (DAGs) to depict the causal relationships
between mediator variables, the exposure (race), and the outcome (ED
visits and hospitalizations for severe hypoglycemia)
d. To quantify the causal effect of each mediator variable proposed in the
DAG using inverse probability weighting to estimate the counter factual
disparity measure1
Hypothesis: We expect that Black patients will have higher rates of severe outpatient
hypoglycemia requiring ED visits and hospitalizations than White, Asian, and Latino
patients in the overall cohort and in the subgroup of insulin users.39 We anticipate that our
proposed DAG based on literature review and expert clinical knowledge will include
multiple factors potentially mediating these disparities. We expect that the most
important mediators will be the use of urgent vs preventative care (which may be, in turn,
mediated by neighborhood deprivation and measures of low socioeconomic status) and
the presence of established long-term diabetic complications and comorbidities, including

1

These analyses are ongoing and results are not presented in this thesis
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chronic kidney disease, which are more common among Black compared with White
patients with diabetes.49
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Methods
Aim 1: Hospital-Acquired DKA
Overall Design: Root Cause vs Common Cause Analysis
One common way to examine preventable iatrogenic complications is by using root
cause analysis. Root cause analysis is a structured method of analysis that aims to
identify a problem, determine the root cause of the problem, and design an intervention to
prevent future occurrences of the same problem. In 2015, The Joint Commission released
an article titled “Root Cause Analysis in Healthcare: Tools and Techniques,” which
detailed the types of problems that can be addressed by RCA and step-by-step guidelines
on using RCA to address them.50 The Joint Commission now requires hospitals to
perform RCA for all sentinel events and develop appropriate interventions to prevent
their reoccurrence.50 Therefore, RCA is used routinely in healthcare across the US.
Despite its widespread use, there is little evidence that RCA is effective in improving
patient safety or reducing adverse events.51 In part, this may be due to how it is
performed. Many healthcare professionals report that limitations in time, resources, and
feedback as well as difficulty collaborating with RCA team members and managers
impact their ability to perform thorough and effective RCAs.52 Even when RCAs are
completed, less than 10% of the resulting recommendations are found to be effective and
sustainable.53 In addition, RCA is impractical to use for events that occur more than once
because each intervention is targeted for one individual case. As a result of these
problems, many hospitals have reported reoccurrences of events after RCAs.51
One proposed solution to the problems with RCA is common cause analysis (CCA).
CCA is based closely on RCA, but instead of focusing on one event, it uses aggregate
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data from multiple cases. Using multiple cases, it is possible to identify factors that
contribute to multiple events. Interventions targeting these common causes have the
potential for greater impact than interventions addressing the cause of one isolated
event.54,55

Setting and Participants
Our study included adult patients who developed DKA during a hospital
admission at Yale New Haven Hospital (YNHH) between Feb 1 2013 and Nov 1 2018.
YNHH is a non-profit teaching hospital that serves residents of Connecticut. It has
approximately 1.4 million outpatient encounters and 76,000 inpatient admissions
annually.
At YNHH, the majority of inpatient diabetes care is provided by patients’ primary
teams. However, there are several exceptions. One is on the podiatry service, where all
patients with diabetes are followed by a medicine consult team for diabetes management.
Another exception is when the primary service is unable to manage a patient’s diabetes.
In this case, the primary team can call the inpatient diabetes management team or the
endocrinology service for consultation. The inpatient diabetes management team consists
of nurse practitioners who specialize in inpatient hyperglycemia. 56 The endocrinology
service is available for consultation on all endocrine-related issues and is staffed by
physicians. Both consult services see patients daily. Of note, per YNHH guidelines, all
inpatients with an insulin pump should be followed by the endocrinology service.
All inpatient admissions for adults over age 18 years with a discharge diagnosis of
DKA were identified from the electronic medical record using ICD-9-CM and ICD-10
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codes. The codes for DKA were 250.10 – 250.13 and E10.10, E10.11, E11.00, and E
11.01.57 Patients were excluded if any of these codes were present on admission or if
DKA was documented in the admission note. After this list of admissions was selected,
the diagnosis of DKA was confirmed by the following criteria: blood glucose >250
mg/dL and bicarbonate <18 mEq/L and one of the following two criteria: anion gap >16
or B-Hydroxybutyrate >3 mmol/L.58 All values had to occur within a 12-hour period. The
date of DKA was the first time during the admission that the patient met all DKA criteria.
The mean and range of values of DKA criteria for all included patients can be found in
Appendix A.
All data were obtained by chart review performed by the author. Date of death
was determined by chart review or by first missed appointment due to death through the
end of the study period (Nov 1 2018). This study was deemed exempt from continuing
review by the Yale University Human Investigations Committee (HIC).

Main Outcome Measures
DKA etiology in each case was determined using the following criteria for mutually
exclusive categories that were determine a priori (based on prior literature and clinical
experience):
1. Insulin dose reduction – Dose of basal insulin reduced within 24 hours prior to
DKA by at least 50% of the outpatient dose.
2. Missed insulin dose – At least one missed dose of basal insulin for any reason
in prior 24 hrs.
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3. Infection – Patient met criteria for sepsis (defined as a suspected source of
infection plus two of the following: temperature >38 or <36, heart rate >90,
respiratory rate >20 or PaCO2 < 32mm Hg, WBC >12,000/mm3, <4,000/mm3,
or >10% bands).59 Of note, one patient who did not meet sepsis criteria, but
had a suspected source of infection and was on antibiotics was categorized as
having a “suspected infection” and was included in this category.
4. Steroids – Patient did not meet any DKA criteria before initiation of steroids
and did meet criteria after initiation of steroids (at any dose) with no insulin
dose reduction or missed doses of insulin.
5. Other – Patients who did not fall into any of the categories above were
classified as “other” and the reason for DKA was determined by progress
notes from the primary team or endocrine consult service if available.

Statistical Analysis
Demographic and clinical variables were described using frequencies and means
for categorical and continuous variables, respectively. DKA etiology was determined by
chart review and the frequencies for each category were reported. In addition, ten charts
were also reviewed by Kasia Lipska, MD and the rate of agreement (kappa) for the chief
reason for DKA was assessed. Kappa statistic was 70% (for this analysis, the missed vs.
reduced insulin dose categories were combined).
Data were entered into a Microsoft Excel spreadsheet and analyzed using JMP
V13.0. All analyses were performed by the author (CZ).
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Aim 2: Severe Outpatient Hypoglycemia
Overall Design: Directed Acyclic Graphs and Mediation Analysis
While common cause analysis is an effective tool for analyzing iatrogenic
complications on a small scale, it is not feasible to perform on a large scale because it
requires analysis of individual cases. An alternative method for examining causal factors
for iatrogenic complications on a larger scale is mediation analysis using directed acyclic
graphs (DAGs). This process allows for causal analysis of many cases simultaneously
while minimizing confounding bias.
DAGs are visual representations of relationships between variables that are used
to model causality. They are useful in observational trials to identify confounders and
determine ways to resolve them based on explicit assumptions. DAGs consist of variables
connected by arrows. Each arrow represents the causal effect of one variable on another.
Following the path of arrows from one variable to the next is a visual representation of a
series of cause and effect relationships. Each pathway through a DAG is called a directed
path. No directed path in a DAG will lead back to its starting point because the cause and
effect relationships are unidirectional and acyclic.
A simple example of a DAG is shown in Figure 1a. In this figure, the exposure
(X) influences the outcome (Y) directly. The arrow from X to Y represents the direct
causal relationship between the exposure and the outcome. In our examination of severe
hypoglycemia, the exposure (X) is race and the outcome (Y) is an ED visit or
hospitalization for severe hypoglycemia. This simplified DAG represents our hypothesis
based on previous research that race influences the rate of ED visits and hospitalizations
for severe hypoglycemia. However, the purpose of our analysis is to investigate which

15

variables mediate this relationship between race and severe hypoglycemia. To answer
that question, we need to represent these variables in our DAG.

Figure 1: Simplified Theoretical Directed Acyclic Graph

b)

a)

M
X

Y

Exposure: Race/Ethnicity

Severe Hypoglycemia

Insulin Use

X

Y

Exposure: Race/Ethnicity

Severe Hypoglycemia

c)

Diabetes Type

C
M
Insulin Use

X

Y

Exposure: Race/Ethnicity

Severe Hypoglycemia

In Figure 1b, there is an additional variable (M) between our exposure and
outcome. This is a mediator variable because it is affected by the exposure and in turn
affects the outcome. The addition of M creates an indirect pathway between X and Y. It
does not erase the effect of X on Y directly, because we do not believe that all of the
impact of X on Y goes through this mediator, M. In fact, by adjusting for the mediator
(M) in our model we can determine how much of the effect of X on Y is a result of the
mediator. For example, if M is insulin use, examining the racial disparities in severe
hypoglycemia after controlling for insulin use will allow us to assess the impact of insulin
use on the relationship between race and severe hypoglycemia.
In addition to mediators, confounder variables can impact the causal relationships
represented in DAGs. Confounders are variables that affect both the exposure or mediator
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and the outcome. Therefore, they limit our ability to assess the effect of the exposure or
mediator on the outcome by creating a “back-door path.” In Figure 1c, a confounder
variable (C) is added to the DAG that causes both the mediator (M) and the outcome (Y).
This confounder could be diabetes type. Patients with type 1diabetes are more likely to be
prescribed insulin than patients with type 2 diabetes and are also more sensitive to
insulin, meaning they are more likely to develop severe hypoglycemia. Therefore, it is
difficult to assess the effect of insulin on the relationship between race and hypoglycemia
without controlling for diabetes type.
Although this example DAG is simplified, it demonstrates the importance of
identifying causal relationships between variables that impact the exposure and outcome
of interest. This process is based on a priori knowledge, which is most often a
combination of literature review and expert clinical input. When all relevant variables
and relationships are represented, it is possible to identify both direct, indirect, and
confounding interactions. These interactions can be used to develop statistical models
that minimize bias in data interpretation.
In summary, the process of creating and analyzing a DAG minimizes bias in
mediation analysis particularly when using data from observational studies in which bias
cannot be minimized by randomization. As such, DAGs are a useful tool for mapping out
potential causal mediator variables, such as the factors mediating the racial disparities in
severe outpatient hypoglycemia.
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Mediator Variable Selection
Mediator variables for the DAG were selected based on a combination of
literature review, unpublished data, and expert opinion. The literature search was
performed in PubMed and limited to articles published from 1999-2019 in English. Two
areas were explored to create a comprehensive list of factors that may mediate racial
disparities in hypoglycemia including (with search terms listed in parentheses):
1. Risk factors for hypoglycemia ((“hypoglycemia”[Title] OR
“hypoglycaemia”[Title]) AND “severe” AND (“risk” OR “predict”) AND
“diabetes”) – 692 results, 10 included plus 4 from cross-reference
2. Factors mediating racial disparities in diabetes and other diabetic
complications ((“race”[Title/Abstract] OR “ethnic”[Title/Abstract]) AND
“diabetes”[Title/Abstract] AND (“disparities” OR “differences”)) – 4584
results, 8 included plus 7 from cross-reference
Articles were included based on relevance. After the literature search, additional
mediator variables were added based on unpublished data from KPNC and expert clinical
opinion from endocrinologist Kasia Lipska, MD. The DAG was created using all
identified mediator variables after thorough discussion with all authors (CZ, KL, AK,
MW).

Inverse Probability Weighting and Counterfactual Disparity Measures
After creating a DAG to depict the causal interactions of our proposed mediator
variables, we plan to estimate the causal effects of each mediator variable by determining
its counterfactual disparity measure with inverse probability weighting. The
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counterfactual disparity measure for each variable is a measure of that variable’s causal
effect on the outcome with minimal contributions from confounding variables.
Counterfactual disparity measures are especially useful in observational studies when
randomization of participants to the exposure of interest is not possible. This is true of
our study, in which the exposure of interest is race. Since race is an inherent
characteristic of an individual (and this is an observational study), it is not possible to
randomize each participant to a racial or ethnic group and observe the effect that their
assigned race/ethnicity has on their risk of severe outpatient hypoglycemia. Therefore,
each race or ethnic group will contain a sample of the population that is not random. As a
result, it is likely that there are differences in baseline characteristics between groups.
We suspect that some of these differences in baseline characteristics are
contributing to the observed racial differences in severe outpatient hypoglycemia. For
example, if Black patients are more likely to use urgent care (such as the ED) for any
cause instead of outpatient care than White patients, this may account for some of the
racial differences in ED visits and hospitalization for hypoglycemia.
In order to estimate the effect of these baseline mediator variables, we can use
inverse probability weighting to estimate the counterfactual disparity measure.
Conceptually, inverse probability weighting assigns all subjects a certain value for the
mediator variable. In our example, we would assign all patients to either no ED visits (for
any cause) in the prior year or 1 ED visit (for any cause). Within each category, we
would then determine the persistent racial differences (i.e. the difference in the rate of
severe hypoglycemia among Black and White patients who had no ED visits and the
difference in the rate of severe hypoglycemia among Black and White patients who had

19

1 ED visit). If prior ED visits accounted for 100% of the racial disparities in severe
hypoglycemia, racial differences among the two groups would disappear in this analysis.
Conversely, if prior ED visits did not account for any of the observed racial disparities,
the racial disparity within each group would be as large as the racial disparity in the full
cohort. The resulting risk difference after inverse probability weighting analysis is known
as the counterfactual disparity measure (because it is not true that all patients are in one
group).
In reality, we do not expect to find one mediator variable that accounts for 100%
of the racial difference in severe hypoglycemia. However, using inverse probability
weighting to estimate the counterfactual disparity measure for each mediator variable of
interest, we can estimate the causal effects of the variables proposed in our DAG.
Given the amount of work that goes into defining variables, creating models, and
running analyses, we plan to start with the variables we believe have the strongest causal
effects on the observed racial differences in ED visits and hospitalizations for severe
hypoglycemia based on literature review and expert clinical knowledge as described
above.

Setting and Study Population
Kaiser Permanente of Northern California (KPNC) is a large, integrated managed
care consortium that provides inpatient and outpatient healthcare for approximately 30%
of residents in Northern California. KPNC has a diabetes registry for all patients with
diabetes that is updated annually and now includes over 350,000 patients. Patients with
diabetes are identified for this registry using multiple data sources including pharmacy
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use, laboratory results, and diagnoses from outpatient visits, ED visits, and
hospitalizations. Details on the algorithm used to identify patients are published
elsewhere.49,60 Patient race and ethnicity was determined by self-report in the Kaiser
electronic medical record.
As mentioned above, the purpose of the DAG and inverse probability weighted
analysis is to visually represent and accurately assess relationships between all known
exposure, mediator, confounder, and outcome variables. However, we recognize that not
all variables and their interactions are currently known. Therefore, in addition to DAG
analysis it is important to control for as many confounding variables as possible by
creating a relatively homogeneous population except for the exposure of interest. A large
part of this was already completed in our choice of study population because access to
healthcare at KP is relatively equal across patient demographics. To further limit
unknown confounding, we restricted our study population to patients on insulin at home.
All included patients had KP membership and prescription benefits for at least
one year prior to the study start period. Patients on insulin were identified by prescription
records demonstrating at least 1 fill in the 6 months prior to 7/1/17. ED visits and
hospitalizations for severe hypoglycemia were identified using ICD codes according to a
validated definition (251.0, 251.1, 251.2, 962.3, or 250.8 modified by 259.8, 272.7, 681,
682, 686.9, 707.1-707.9, 709.3, 730.0-730.2, or 731.8).61 Cohort identification was
performed by Margaret Wharton, MPH at KP due to restrictions on data access to
researchers outside of the KP system.
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Statistical Analysis
The combined number of ED visits and hospitalizations for severe hypoglycemia
was calculated for the study period and divided by the number of person years of followup to determine the event rate per 1,000 person-years. This was calculated for the full
cohort as well as by race/ethnicity and insulin use. Rates are reported as mean [95%
confidence interval], although confidence intervals were calculated only for subgroups by
race and insulin use and not for the full cohort.
Future mediation analyses will be performed by Margaret Wharton, MPH at
KPNC. Briefly, counterfactual disparity measures will be calculated for each mediator
variable of interest using inverse probability weighted regression models (marginal
structural models). From these models, we will get an estimate of how much of the
observed racial disparities in severe hypoglycemia events requiring ED visits or
hospitalizations is attributable to the mediator variable of interest.
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Results
Aim 1: Hospital-Acquired DKA
Patient demographics and clinical characteristics are presented in Table 1. A total
of 27 patients were included in our study of hospital-acquired DKA (Figure 2). These
patients had a mean age of 53.4 years, and were predominantly female (59.3%) and white
(70.4%). The majority of cases were Type 1 diabetics (59.3%), but approximately one
quarter (25.9%) had an unspecified diabetes type based on ICD codes and chart review.
All except one patient used insulin at home and the majority (70.4%) were on a basal
bolus regimen prior to admission (details and definitions of insulin regimens are found in
Appendix B). The mean HbA1c within 3 Figure 2: Inclusion Criteria for HospitalAcquired DKA Chart Review
months of admission was 8.9%+2.2.
On admission, the mean blood
glucose was 193+102. 16 patients
(59%) were hypoglycemic during the
admission (blood glucose <70 mg/dL).
Of these, 10 were hypoglycemic
before developing DKA, 13 were
hypoglycemia after developing DKA,
and 7 were hypoglycemic both before
and after developing DKA. Twentyone patients (77%) were on a teaching
service at the time of DKA development, and 7 (25.9%) were in an intensive care (ICU)
or step-down unit (SDU).
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Table 1: Demographics and Clinical Characteristics of Patients with HospitalAcquired Diabetic Ketoacidosis.
N
27
Age, years, mean (SD)
53.4 (11.5)
Female gender, n (%)
16 (59.3%)
Race/ethnicity, n (%)
Black
3 (11.1%)
White
19 (70.4%)
Hispanic*
5 (18.5%)
Diabetes type, n (%)
Type 1
16 (59.3%)
Type 2
4 (14.8%)
Unspecified
7 (25.9%)
Diabetes treatment at home, n (%)
Basal bolus insulin
19 (70.4%)
Basal insulin only
1 (3.7%)
Basal bolus insulin plus orals
3 (11.1%)
Basal insulin plus orals
1 (3.7%)
Insulin pump
2 (7.4%)
Orals only
1 (3.7%)
HbA1c, mean (SD) (n=20)
8.9 (2.2)
Admission glucose, mean (SD)
193 (102)
Hypoglycemia (<70mg/dl), n (%)
Total during this admission
16 (59%)
Before DKA only
3
After DKA only
6
Before and after DKA
7
Teaching service, n (%)
21 (77.8%)
In ICU or SDU at time of DKA onset, n (%)
7 (25.9%)
*All patients who identified as Hispanic had were listed as “unknown” race in EMR
Legend: ICU, intensive care unit; SDU, step-down unit
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At the time of DKA development, 14 patients

Figure 3: Primary Service
at time of DKA

(51.9%) were on a medicine or neurology service (13
medicine, 1 neurology), 9 (33.3%) were on a surgery or
ob/gyn service (8 surgery, 1 ob/gyn), and 4 (14.8%) were
on a podiatry service (Figure 3).
Consults before and after DKA are depicted in
Figure 4. Briefly, all patients on the podiatry service had
consults to medicine regarding their diabetes (3 of 4 cases) or the diabetes team (1 of 4
cases) before the development of DKA. On medicine and surgery, rates of consults
related to diabetes were lower before the development of DKA. Prior to DKA, 11 of 12
patients on medicine and 7 of 9 patients on surgery had no diabetes related consults. After
DKA, 5 patients on surgery received new consults to either medicine, endocrine, or the
diabetes team. On medicine, 3 patients received new consults to endocrine or the diabetes
team. 10 patients had no consults before or after DKA.

Figure 4: Consults before and after DKA
Primary Service
Podiatry
4 Cases

Consults
4 Cases

Surgery or Ob/Gyn
9 Cases

Medicine or Neurology
12 Cases

No Consults
0 Cases

Consults
1 Case

No Consults
11 Cases

Consults
2 Cases

No Consults
7 Cases

Consults
3 Cases

No Consults
8 Cases

Consults
5 Cases

No Consults
2 Cases

Consults Pre-DKA
New Consults Post-DKA

Consults
1 Case

No Consults
3 Cases

Consult Type

= Medicine

= DM Team

= Medicine & DM Team

= Endocrine
= Endocrine & DM Team

Legend: DM Team – diabetes team
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Of note, out of 7 cases with consultants, 4 developed DKA due to insulin dose
reduction or a missed insulin dose. In 2 of these 4 cases, consultants recommended a
higher or extra dose of insulin in the consult note that the patient never received.
Patients developed DKA a median of 2 days after admission with a range of 0-15
days. This did not differ across services. In the 24 hours prior to DKA, 12 patients
(44.4%) received doses of basal and bolus insulin. Eight patients (29.6%) received bolus
insulin only and 3 patients (11.1%) did not receive any insulin. One patient (3.6%) was
on an insulin pump prior to DKA and 2 (7.4%) were on insulin infusions. Twelve patients
(44%) received steroids in the 24 hours prior to DKA. Data on precipitating factors and
medications in the 24 hours prior to the development of DKA are shown in Table 2.
Table 2: Treatment Characteristics of Patients with Hospital-Acquired DKA and
DKA Etiology
Time to DKA, days (median, range)
2 (0-15)
Insulin administered within 24 hrs prior to DKA, n (%)
Basal and bolus insulin
12 (44.4%)
Bolus insulin only
8 (29.6%)
None
3 (11.1%)
Insulin pump
1 (3.7%)
Insulin drip
2 (7.4%)
Insulin drip and bolus insulin
1 (3.7%)
Steroids within 24 hrs prior to DKA, n (%)
12 (44.4%)
Reason for DKA, n (%)
Missed doses of insulin
7 (25.9%)
Insulin dose reduction
8 (29.6)
+
4 (14.8%)
Infection
Steroids
4 (14.8%)
Other*
4 (14.8%)
+Includes one case of suspected infection that did not meet SIRS criteria
*Per chart DKA was attributed to physiologic stress from shock, surgery
The majority of cases appeared to be caused by problems with insulin dosing,
including missed doses of insulin (7 cases, 25.9%) and insulin dose reduction of 50% or
greater (8 cases, 29.6%). The causes among the remaining 12 patients were evenly
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distributed between steroids (n=4, 13.8%), infection (n=4, 13.8% including 1 with
suspected infection), and severe stress associated with surgery and shock (n=4, 13.8%).
The etiology of DKA on each primary service was variable (Figure 5). However, 3 of 4
cases attributed to infection were on the podiatry service.
Figure 5: Etiology of DKA by Primary Service

After DKA was diagnosed, 22 of 27 cases were treated with an insulin infusion
for a mean duration of 43.1 hours (range 7-257). Nine of 20 eligible patients were
transferred to an ICU or SDU for DKA treatment. A total of 12 patients (44.4%) died by
the end of the study period (Nov 1 2018). Two of these patients died during the same
hospital admission in which they developed DKA and 1 within one week of discharge.
Treatment and outcomes of cases included in the study are shown in Table 3.
Table 3: Treatment and Outcomes of Patients with Hospital-Acquired DKA
Insulin drip
Yes, n (%)
22 (81.4%)
Duration (hrs), mean (range)
43.1 (7-257)
Transfer to ICU or SDU for DKA (n=20)*
9 (45%)
Mortality
Death by end of study period, n (%)
12 (44.4%)
Time to death from DKA, days, mean (range)
238 (3-1100)
*7 patients were in an ICU or SDU at the time of DKA and were not eligible for transfer
Legend: ICU – intensive care unit, SDU – step-down unit
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Aim 2: Severe Outpatient Hypoglycemia
Study Population
A total of 305,310 patients (including patients on insulin at home and patients not
on insulin at home) were included in this analysis. A flowchart for inclusion/exclusion of
patients is shown in Figure 6.
Figure 6: Inclusion Criteria for Severe Outpatient Hypoglycemia

Rate of Severe Hypoglycemia, Overall and by Race
There were a total of 2391 severe hypoglycemia events requiring an ED visit or
hospitalization from July 2017 – June 2018 at KPNC. The event rate for the full cohort
was 7.83 per 1000 person-years. This rate varied significantly by race. The highest rate
was among Black patients at 13.64 compared to a rate of 9.27 among Whites and 7.65 per
1000 person-years among Latinos (Figure 7).
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Figure 7: Unadjusted Severe Hypoglycemia Rate per 1,000 Person-Years by
Race/Ethnicity Among Patients with Diabetes Mellitus at Kaiser Permanente
Northern California, July 2017-June 2018

Insulin Use, Overall and by Race
For the mediation analysis, only patients on insulin will be included in order to
control for variations in disease severity and duration. Of the full cohort, 23.7% of
patients were treated with insulin. This did not vary significantly between races or
ethnicities (Figure 8). As expected, the rate of severe hypoglycemia among patients on
insulin was higher than the full cohort at 24.72 [23.37, 25.73] events per 1000 personyears (Figure 9). This rate also varied significantly by race. The highest rate was among
Black patients at 34.27 [30.09, 38.87] compared with a rate of 27.14 [25.39, 28.99]
among White patients and 22.14 [19.71, 24.73] among Latino patients. Rates of severe
hypoglycemia among patients not on insulin were significantly lower (3.07 [2.81, 3.27]
events per 1,000 person-years for the full cohort).
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Figure 8: Percentage of Study Population with Baseline Insulin Use by
Race/Ethnicity July 2017-June 2018

Figure 9: Unadjusted Severe Hypoglycemia Incidence per 1,000 Person-Years
By Race/Ethnicity and Baseline Insulin Use July 2017-June 2018
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Directed Acyclic Graphs
In order to facilitate mediation analysis, a DAG was created to visualize the
relationships between the exposure of interest (race) and the outcome (ED
visits/hospitalizations for severe hypoglycemia). This DAG (Figure 10) was created
based on literature review and expert clinical knowledge as discussed in the methods
section, and was the result of multiple discussions among all team members (CZ, KL,
MW, and AK). It depicts the relationships between race and severe hypoglycemia
through categories of mediator variables. These categories were created by grouping
related variables identified in the literature search. They include sociodemographics and
social determinants of health, health literacy, comorbidities and healthcare utilization,
and health behavior. Briefly, justifications for each category of variables and their
interactions in the DAG are laid out below.
Figure 10: Directed Acyclic Graph of the Race (X) Severe Hypoglycemia (Y)
Relationship

Legend: NDI – Neighborhood Deprivation Index; LEP – Limited English Proficiency;
CKD – Chronic Kidney Disease; CVD – Cardiovascular Disease; SF-1 Self-Rated Health
Form; IP – Inpatient; PCP – primary care provider; SMBG – Self-monitoring of blood
glucose
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Comorbidities and Utilization
Multiple clinical factors and comorbidities are associated with increased rates of
severe hypoglycemia among diabetic patients.44,62,63 The most well studied of these risk
factors include longer duration of diabetes and treatment,30 use of sulfonylureas or
insulin,63 increasing number of antidiabetic medications,43 cardiovascular disease,64
dementia,65 depression,66 and CKD.67 Measures of overall illness burden such as the
Charlson Comorbidity Index (CCI, Appendix C) have also been shown to be significant
independent risk factors for the development of severe hypoglycemia.40,62 This is likely
caused by inclusion of several of the well-studied risk factors for hypoglycemia in the
CCI as well as inclusion of other risk factors for hypoglycemia that have not yet been
thoroughly investigated. In addition, higher overall disease burden as measured by the
CCI may decrease awareness of hypoglycemia and thus the ability to identify and treat it
before it becomes severe.
Many of these clinical risk factors and comorbidities including CKD68 and
cardiovascular disease69 are present at higher rates in African Americans.49,70 Racial
disparities in any one (or some combination) of these clinical factors may be contributing
to the observed racial disparities in ED visits and hospitalizations for severe
hypoglycemia.
The racial disparities observed in our data may not only be the result of increased
risk of severe hypoglycemia among Black patients, but also differences in healthcare
utilization patterns resulting in increased use of the ED for hypoglycemic episodes. In
fact, increased use of urgent care for any reason is associated with increased risk of
hypoglycemia requiring an ED visit or hospitalization.63 This pattern of decreased use of
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preventive care and increased use of urgent care (including the ED) has been previously
identified in Black patients compared to White patients with diabetes in populations with
access to healthcare.71,72 Because healthcare utilization is closely related to comorbidity
burden in patients with access to healthcare such as patients at KPNC, these variables
were grouped together in our DAG.

Sociodemographics and Social Determinants of Health
Sociodemographic and social determinants of health together form a measure of
social vulnerability, which is defined as the reduced ability of a person to respond to or
withstand external adverse events. Higher social vulnerability is an independent risk
factor for hypoglycemia among patients with diabetes. 73 In addition, several individual
components of social vulnerability are associated with an increased risk of hypoglycemia
and other diabetic complications. For example, sociodemographic characteristics
including age, sex, place of birth, education, and social support have been shown to affect
health outcomes such as HbA1c among diabetic patients with access to a standardized
healthcare system.74,75 Socioeconomic factors such as low household income are also
associated with increased risk of hospitalization and reduced use of preventive care
among insured patients with diabetes.76,77
Many sociodemographic factors and social determinants of health also vary by
race and ethnicity. Racial disparities in self efficacy and social support at home have been
observed and are thought to contribute to observed racial differences in self-management
of hypoglycemia.78 Previous studies have shown that differences in English proficiency
may also account for some of the ethnic differences in preventive care use. 71
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Together, these data demonstrate the importance of careful consideration of social
vulnerability in the relationship between race and ED visits and hospitalizations for
severe hypoglycemia.

Health literacy
Adequate health literacy is necessary in order to understand disease, make
healthcare related decisions, and follow treatment recommendations. It is especially
important in managing chronic diseases such as diabetes, which require consistent and
appropriate preventive care. Among patients with diabetes, lower health literacy is
associated with an increased risk of hypoglycemia and poor glycemic control.79,80 Health
literacy is also thought to mediate the association between low socioeconomic status and
multiple poor health outcomes such as increased rates of diabetic complications.78,81,82
Black patients are disproportionately affected by inadequate health literacy with
approximately 24% of Black patients having below basic health literacy compared to 9%
of White patients.83 These data suggest that health literacy may be an important mediator
of the relationship between race and severe hypoglycemia even though it is not directly
affected by race itself.

Health Behaviors
Health behaviors include adherence to medications, attendance at healthcare
visits, and daily management of health at home. For patients with diabetes, this includes
regular monitoring of blood glucose, routine preventive care appointments, and consistent
use of prescribed medications. Certain health behaviors, such as adherence to
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appointments and medications are associated with improved glycemic control and
reduced risk of hospitalizations in patients with diabetes.84,85
Important health behaviors such as self-monitoring of blood glucose and use of
preventive care have been shown to vary across racial and ethnic groups.71,72,86 As with
health literacy, there is no evidence that race impacts health behaviors directly. The
relationships between race and health behaviors may instead be mediated by social
vulnerability and health literacy.81,87

Variable Interactions
Accurately depicting the relationships between these variables in the DAG is
important in order to minimize bias and confounding in the inverse probability weighted
analysis. Based on the evidence above, we created the following description of variable
interactions (with direct relationships represented as arrows in the DAG in Figure 10):
1. Relationships between mediator variables and the outcome variable. All mediator
variables directly impact the rate of ED visits and hospitalizations for severe
hypoglycemia.
2. Relationships between race and mediator variables. Race impacts the following
variable categories:
a. Sociodemographics and social determinants of health
b. Comorbidities and utilization
3. Relationships between mediator variables. Mediator variable interactions are as
follows:
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a. Sociodemographics and social determinants of health impact health
literacy, health behaviors, and comorbidities and utilization.
b. Health literacy impacts health behaviors and comorbidities and utilization

Future Results
Inverse probability weighted modeling will result in estimates of the causal
contribution of each mediator variable of interest on the observed racial disparities in ED
visits and hospitalizations for severe hypoglycemia. An example of this analysis for all
cause ED visits in the prior year is shown in Appendix D.
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Discussion
Aim 1: Hospital Acquired DKA
In summary, we identified 27 cases of hospital-acquired DKA between Feb 1, 2013
and Nov 1, 2018 at a large teaching hospital. The majority of patients had type 1 diabetes
and were on basal bolus insulin regimens at home. They were admitted to a variety of
different hospital services and 7 patients had consults related to their diabetes prior to the
development of DKA. Patients developed DKA a median of 2 days after admission and
the majority of cases were caused by problems with insulin dosing including missed
doses and dose reduction by 50% or more. In the same admission in which they
developed DKA, 16 patients also experienced episodes of hypoglycemia. Of all 27
patients, 12 were deceased by the end of the study period.
These data highlight three challenges in caring for diabetic patients that may be
contributing to the development of hospital-acquired DKA. The first challenge is the
transition to inpatient management as demonstrated by the occurrence of many cases of
hospital-acquired DKA within 48 hours of admission. The second challenge is
communication between co-managing teams given the development of DKA despite the
involvement of expert consultants. The third challenge is labile blood sugars as shown by
the large proportion of cases with hypoglycemia during the same admission. Below, each
challenge is discussed in detail.

1. Transition to inpatient management
In our study, hospital-acquired DKA occurred a median of 2 days after admission.
This suggests that diabetic patients are especially vulnerable to hospital-acquired DKA
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within the first 48 hours of admission. On average DKA takes less than 24 hours to
develop, meaning that many cases began to develop shortly after hospital admission.
Given that the majority of cases were caused by problems with insulin dosing, this
finding likely highlights challenges providers face in determining which types of insulin
to use in the inpatient setting and their appropriate doses. Inappropriate insulin orders
placed on admission can cause hospital-acquired DKA within the first 48 hours.
In addition, in approximately one quarter of cases, the type of diabetes was not
specified either by ICD code or in the text of the admission note. Unspecified diabetes
type may hinder appropriate glycemic control (e.g. due to the absolute requirement for
insulin in patients with type 1 diabetes) and could be an indicator that diabetes
management was not prioritized during the hospital admission.
Challenges with documenting the correct diabetes types, choosing which insulin types
to continue in the inpatient setting and selecting an appropriate dose appear to be
contributing to many cases of DKA that occur within the first 48 hours of admission
given that many of these cases are caused by inappropriate insulin dosing. Missed and
reduced doses of insulin are common in the transition to the inpatient setting due to
changes in patients’ diets and environments. Assessing patients’ insulin needs at the time
of admission depends on knowledge of that patient’s diabetes type, treatment regimen at
home, and diet in the hospital. Even with this information, glycemic control requires dose
adjustments based on frequent blood glucose monitoring throughout the hospitalization.
Additional challenges arise when a patient is admitted for a problem unrelated to their
diabetes because the reason for admission may be prioritized over glycemic control both
during the admission and throughout the hospital stay.
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To address the difficult transition from outpatient to inpatient management of
diabetes, we propose the following:
a. Expand the admission insulin order set to provide more detailed instructions
on dosing of basal and bolus insulin including suggested dosing based on
outpatient regimen and hospital diet
b. EMR alerts for insulin dose reduction of >50% of outpatient dose or
discontinuation of basal insulin in patients on outpatient basal regimens or
those with type 1 diabetes
c. Re-categorization of diabetes in the EMR problem list and past medical
history to encourage specification of diabetes type

2. Communication between co-managing teams
In 7 of 27 cases, a consult service (including medicine, endocrine, or the diabetes
team) was following the patient’s diabetes prior to the development of DKA. In these
cases, diabetes management is typically the responsibility of the consulting specialists
and problems with glycemic control caused by insulin dosing may be due to decisions
made by the consultants and not the primary service. However, on further investigation it
became apparent that consultant recommendations were not always communicated or
carried out.
Multiple teams managing diabetes in a single patient can cause challenges in the
creation, communication, and follow-through of the diabetes management plan. These
challenges were evident among patients who developed DKA on the podiatry service
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while being managed by a consulting medicine team and patients with endocrine or
diabetes team consultants.
To address the challenges in communication between co-managing teams, we
propose the following:
a. Assessment of communication barriers between consultants and primary
services about diabetes management using qualitative/narrative interviews

3. Labile blood sugars
A majority of patients in our study were hypoglycemic during the same admission
they developed DKA. Ten patients were hypoglycemic before the development of DKA
and 6 were hypoglycemia after. Progress notes in several charts mentioned concern for
hypoglycemia as rationale to lower or discontinue basal insulin. These appropriate
concerns raise additional challenges – the risk of hypoglycemia needs to be balanced
against the risk of DKA, each one of which can develop acutely when insulin is given in
excess or when it is held or reduced, respectively.
To address the challenges in managing diabetic inpatients with labile blood
glucose we propose the following:
a. Addition of dose adjustment suggestions to the EMR insulin order based on
real time blood glucose levels [One proposed solution using an algorithm for
insulin dosing suggestion is found in Maynard et al (Appendix E).88 This
algorithm walks providers through appropriate dosing based on the patient and
their diet while in the hospital. It also includes adjustments based on hyper or
hypoglycemia. An algorithm like this could be integrated into admission
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orders as well as programmed to suggest dose adjustments based on real-time
blood glucose results.]
b. Educational intervention for providers on the appropriate basal/bolus regimens
to minimize both hyper and hypoglycemia88

Limitations
Although we know that hospital-acquired DKA is not unique to our hospital, the
results of this study may not be generalizable across institutions because it was performed
at a single site. However, the purpose of this analysis is to call attention to the existence
of hospital-acquired DKA and highlight common cause analysis as a method of
investigating and addressing these events. Using this approach, hospitals will be able to
identify and address causes of DKA specific to their institution. This type of approach
will allow for the most effective, tailored interventions. As other hospitals and individuals
perform their own analyses, it is likely that some of the causes will be similar across
institutions. Implementing and monitoring interventions directed at these common causes
could provide useful data for hospitals across the country aiming to reduce cases of
hospital-acquired DKA.
This analysis likely vastly underestimates the incidence of hospital-acquired DKA
because it relies on appropriate ICD coding and uses strict criteria for DKA. Many cases
of DKA are not coded as such because of errors in coding or diagnosis. Although
quantifying the incidence of hospital-acquired DKA is important in order to understand
the scope of the problem, that was not the aim of this analysis. The purpose was to find
the most severe, unquestionable cases of hospital-acquired DKA in order to describe
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patterns in precipitating factors that can lead to the development of targeted interventions.
Other, less severe cases likely have similar causes that were recognized and addressed
before they reached DKA that would qualify for our study. Interventions targeted at the
most severe cases may also address these cases of incipient DKA.
Not only does relying on chart documentation lead to an underestimation of the
number of cases of DKA, but it also may have limited our ability to understand the cases
of hospital-acquired DKA that we did identify. Not all events that occur during an
inpatient admission are documented in the chart. Furthermore, providers may be less
likely to document adverse events especially when they are iatrogenic. When reviewing
cases, we made every effort to use objective data such as records of insulin
administration and sepsis criteria. We also used multiple sources of notes from primary
teams, consultants, and nursing staff. However, we understand that we may still have
missed important events due to a lack of documentation.

Next Steps
This analysis sought to identify the patient population and clinical context in
which hospital-acquired DKA develops at a large teaching hospital using common cause
analysis. Identification of patterns in causes of hospital-acquired DKA is the foundation
of the development of effective and targeted interventions. At this point, we have
characterized patient, clinical, and institutional factors that contributed to the most
serious cases of DKA identified by ICD codes. However, there is still work to be done.
We have several ongoing and future initiatives to better understand and address
hospital-acquired DKA. First, as mentioned above, we are working to address each
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specific challenge identified in our study with a targeted intervention. In order to do so
effectively, we are collaborating with Dr. Steven Choi, the chief quality officer of
YNHH. Second, we plan to use laboratory values to identify patients with hospital
acquired DKA regardless of whether or not it was coded appropriately. We can further
examine these cases to understand not only why it occurred, but what prevented accurate
and timely diagnosis if applicable. Finally, we are looking to share our results with other
institutions. This will help us call attention to hospital-acquired DKA and identify
collaborators with whom we can identify and address common causes. The manuscript
based on this work will be submitted for publication (with CZ as the lead author). With
these efforts, we aim to reduce cases of inpatient DKA at our hospital and others in the
US.
Aim 2: Severe Outpatient Hypoglycemia
Our analyses of 305,310 patients of KPNC demonstrated racial disparities in rates
of severe outpatient hypoglycemia requiring ED visits or hospitalizations. These
disparities were consistent with prior studies.41,89 We did not find significant differences
in insulin use between races and ethnicities despite previous research demonstrating a
higher rate of insulin use among Black patients. This may be a result of standardization of
access and diabetes management in the KP system. This finding allows us to restrict our
study population to patients on insulin in order to create a more homogeneous study
population.
In our DAG, we proposed that the observed racial disparities in severe
hypoglycemia are mediated by several categories of factors including sociodemographic
factors and social determinants of health, comorbidities and healthcare utilization, health
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literacy, and health behaviors. We expect each variable in the DAG to contribute to the
disparities to varying degrees. However, assessing the impact of all of these variables
using inverse probability weighting to determine the counterfactual disparity measure is
impractical at this stage. Therefore, we plan to start with the variables we believe have
the highest impact according to our literature review and expert clinical knowledge.
We expect that racial disparities in severe hypoglycemia are primarily driven by
differences in healthcare utilization patterns. Severe hypoglycemia requiring an ED visit
or hospital admission involves two steps: the development of hypoglycemia and the
inability to manage hypoglycemia at home. Although research has demonstrated racial
disparities in ED visits and hospital admissions for SH, it is not known whether these
disparities arise from differences in rates of hypoglycemia or differences in ED visits for
hypoglycemia or both.
We suspect that although there may be increased rates of severe hypoglycemia among
Black patients compared to White patients, these differences will not be as great as the
racial differences in ED visits and hospitalizations for severe hypoglycemia because of
increased use of the emergency room for severe hypoglycemia among Black patients
compared to White patients.72 As demonstrated in the DAG, other factors affect
healthcare utilization patterns including sociodemographics and social determinants of
health, health literacy, and health behaviors. Therefore, we expect that a large portion of
the causal effects of other variables may act through differences in patterns of healthcare
utilization. Beginning our analysis by assessing the impact of healthcare utilization
patterns on racial differences in severe hypoglycemia will allow us to work backward in
order to determine the most important causal factors.

44

Limitations
One of the main challenges of this type of study is the identification and measurement
of variables. It is not possible to identify every single variable that mediates racial
disparities in severe hypoglycemia and measure it perfectly. However, that is not the aim
of this study. Instead, the aim is to identify important factors that may be driving the
observed racial disparities in order to understand which variables to target in
interventions to reduce these disparities. Although we may not capture every mediator
variable or measure the effects of each mediator precisely, our analysis will yield
important information on the relative impact of key mediators. This will allow us to
create interventions targeted to reduce disparities in ED visits and hospitalizations for
severe hypoglycemia.
This study also uses the KPNC system, which has detailed information on a large
population of patients with access to care. Racial and ethnic disparities in access to
healthcare in this population are much smaller than in the general US population.
Although this is helpful in identifying other factors that may be mediating disparities in
healthcare outcomes, we do not want to minimize the importance of addressing
disparities in access to care in the general population.

Next Steps
We are currently working to define and measure each variable proposed in the DAG
in order to begin our inverse probability weighting analysis with ED visits for any cause
in the prior year as the mediator variable. Subsequently, we plan to analyze each
proposed variable in a similar fashion. Ultimately, understanding the factors that mediate
the racial disparities in ED visits and hospitalization for severe hypoglycemia will allow
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us to develop the most effective interventions. The manuscript based on this work will be
submitted for publication (with CZ as the lead author).

Conclusions
Taken together, these two projects demonstrate the usefulness of thorough
analysis and description of iatrogenic complications of diabetes. The process through
which we examine and analyze these problems is of the utmost importance and this
project demonstrates two rigorous analyses for cohorts of different sizes. In the hospitalacquired DKA analysis, common cause analysis is used on a small number of cases with
extensive data on each individual case context. In the severe outpatient hypoglycemia
analysis, Directed Acyclic Graphs are created to clearly depict which variables mediate
the relationship between race/ethnicity and severe hypoglycemia and we describe the
analytic plan using inverse probability weighting to estimate counterfactual disparity
measures. These analyses minimize bias and allow for appropriate controlling for
confounders. Although iatrogenic complications of diabetes can be challenging to
examine due to their complex nature, their effects on patient safety are important and
impossible to ignore. Understanding and describing the factors contributing to these
iatrogenic complications is the first step in reducing their occurrence.
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Appendices
Appendix A: DKA criteria
Glucose, mean (range)
HCO3, mean (range)
Anion gap, mean (range)
Beta-hydroxybutyrate, mean (range) (n=16)
pH arterial, mean (range) (n=11)

359 (263-604)
13 (5-17)
25 (17-35)
3.3 (0.08-8.9)
7.35 (7.22-7.49)

Appendix B: Treatment regimens90
Treatment regimens for patients with diabetes mellitus vary based on diabetes
type and severity. In type 1 diabetes, therapy with insulin including both basal (longacting) and bolus (short-acting) or premixed insulin is initiated at the time of diagnosis
because of the absolute insulin deficiency in type 1 diabetes. In type 2 diabetes, the
choice of therapy is dependent on disease severity. After a trial of lifestyle changes, many
patients with less severe disease are initially started on oral medications (often with a 3month trial of monotherapy followed by a 3-month trial of dual therapy). If blood sugars
are not well-controlled on 2 oral medications, basal insulin therapy is often initiated. Due
to the progressive nature of the disease, many patients require therapy intensification
including the transition to basal and bolus or premixed insulins or the use of an insulin
pump later in the course of their disease.
Many of the patients in our study had type 1 diabetes, and were therefore on basal
and bolus or insulin pump regimens. Among patients with type 2 diabetes, the treatment
regimens that include basal and bolus insulin may indicate increased disease severity
compared to patients on basal insulin or oral medications only.
Appendix C: Charlson Comorbidity Index Calculation91
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Appendix D: Inverse Probability Weighted Analysis for All Cause ED Visits in
Prior Year

Legend:
a) Initial DAG with all cause ED visits in prior year isolated as the mediator variable (M).
b) Adjustment for sociodemographics and social determinants of health blocks the
pathway between race and health literacy, health behavior, and comorbidities/utilization.
It is not a collider, so no bias is introduced.
c) Adjustment for health literacy blocks the pathway between race and health behavior.
d) Adjustment for health behavior.
e) Adjustment for comorbidities and utilization removes all other alternate pathways from
race to all-cause ED visits in prior year and race to ED visits/hospitalizations for severe
hypoglycemia.
f) Final DAG with our exposure, outcome, and mediator of interest. Adjustment for this
mediator will determine how much of the effect of race on ED/IP hypo is mediated by all
caused ED visits in the prior year.
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Appendix E: Sample Insulin Dosing Algorithm from Maynard et al88
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